Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Hepato-Gastroenterology

• Publication date

  2011-10-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.5754/hge11263PMID 22024083
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats.

  2011cited by this paper
• Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker

  2010cited by this paper
• Glucagon‐like peptide‐1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

  2010cited by this paper
• Epidemiological aspects of obesity and NASH/NAFLD in Japan.

  2005cited by this paper
• Biological actions and therapeutic potential of the glucagon-like peptides.

  2002cited by this paper
• NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

  2002cited by this paper
• Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation

  1998cited by this paper
• Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

  1995cited by this paper
• Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.

  1993cited by this paper
• The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years

  1990cited by this paper
• Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.

  1980cited by this paper

• The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment

  2025cites this paper
• Review of current and new drugs for the treatment of metabolic-associated fatty liver disease

  2024cites this paper
• Recent approaches for sodium-glucose Co-transporter 2 inhibitors in the management of non-alcoholic fatty liver disease

  2023cites this paper
• Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial

  2023cites this paper
• Factors contributing to the adverse drug reactions associated with the dipeptidyl peptidase-4 (DPP-4) inhibitors: A scoping review.

  2023cites this paper
• Selection and Warning of Evidence-Based Antidiabetic Medications for Patients With Chronic Liver Disease

  2022influential citation
• Efficacy of Sitagliptin on Nonalcoholic Fatty Liver Disease in High-fat-diet-fed Diabetic Mice

  2022cites this paper
• Polycystic ovary syndrome and nonalcoholic fatty liver disease

  2022cites this paper
• Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease

  2022influential citation
• Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs

  2022cites this paper
• Prolonged effects of DPP-4 inhibitors on steato-hepatitic changes in Sprague–Dawley rats fed a high-cholesterol diet

  2022cites this paper
• Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy

  2021cites this paper
• The pathophysiology of gut–liver connection

  2021cites this paper
• Effect of SGLT-2 Inhibitors on Non-alcoholic Fatty Liver Disease among Patients with Type 2 Diabetes Mellitus: Systematic Review with Meta-analysis and Trial Sequential Analysis of Randomized Clinical Trials

  2021influential citation
• Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease

  2021cites this paper
• Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study.

  2021cites this paper
• Effects of the Combination of Evogliptin and Leucine on Insulin Resistance and Hepatic Steatosis in High-Fat Diet-Fed Mice

  2021cites this paper
• Efficacy and tolerability of sitagliptin and metformin compared with insulin as an initial therapy for newly diagnosed diabetic patients with severe hyperglycaemia

  2021cites this paper
• Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan

  2021influential citation
• Effects and Safety of Sitagliptin in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

  2020cites this paper
• Efficacy and safety of incretin-based therapies in patients with nonalcoholic fatty liver disease

  2020cites this paper
• Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis.

  2020cites this paper
• Hepatic steatosis integrated approach: nutritional guidelines and joined nutraceutical administration.

  2020cites this paper
• How to Reduce Cardiovascular Risk in Nonalcoholic Fatty Liver Disease

  2020cites this paper
• Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease

  2020cites this paper
• Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease

  2020cites this paper
• Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease

  2020cites this paper
• Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment

  2019cites this paper
• Impact of exercise training on dipeptidyl peptidase 4 and insulin-like growth factor binding protein 1 in patients with coronary artery disease: Relationship to nitric oxide response

  2019cites this paper
• The efficacy of sitagliptin for non-alcoholic-fatty liver disease: a meta-analysis of randomized controlled trials

  2019cites this paper
• Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease.

  2019cites this paper
• Amelioration of diet-induced metabolic syndrome and fatty liver with Sitagliptin via regulation of adipose tissue inflammation and hepatic Adiponectin/AMPK levels in mice.

  2019cites this paper
• Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: think out of the box!

  2019cites this paper
• Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease

  2019cites this paper
• From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options

  2019cites this paper
• Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease

  2019cites this paper
• Resveratrol Reduces Glucolipid Metabolic Dysfunction and Learning and Memory Impairment in a NAFLD Rat Model: Involvement in Regulating the Imbalance of Nesfatin-1 Abundance and Copine 6 Expression

  2019cites this paper
• In vivo protective effect of Rosmarinus officinalis oil against carbon tetrachloride (CCl4)-induced hepatotoxicity in rats

  2019cites this paper
• Incretin‐Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes

  2019cites this paper
• Current treatment options for nonalcoholic fatty liver disease

  2019cites this paper
• Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?

  2018influential citation
• Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies

  2018cites this paper
• PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease

  2018cites this paper
• Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes

  2018cites this paper
• Primary Prevention of Cardiovascular Disease with Collaborative Diabetes Study in the Efficacy of Statins: Meta-Analysis of Randomized Controlled Trials

  2018cites this paper
• Glucose-Lowering Agents in the Management of Nonalcoholic Fatty Liver Disease

  2018cites this paper
• Significance of circulatory DPP4 activity in metabolic diseases

  2018cites this paper
• NON-ALCOHOLIC FATTY LIVER DISEASE AND DIABETES MELLITUSA TALE OF TWO SINS

  2018cites this paper
• Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non‐alcoholic fatty liver disease and type 2 diabetes mellitus

  2017cites this paper
• Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota.

  2017cites this paper
• Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes

  2017cites this paper
• Novel antidiabetic medications for non‐alcoholic fatty liver disease with type 2 diabetes mellitus

  2017cites this paper
• Treatment options for alcoholic and non-alcoholic fatty liver disease: A review

  2017cites this paper
• Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial.

  2017cites this paper
• The role of incretin hormones and glucagon in patients with liver disease.

  2017cites this paper
• Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice.

  2017cites this paper
• Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models

  2017cites this paper
• Non-alcoholic fatty liver disease and diabetes.

  2017cites this paper
• Gastrointestinal and Cardiovascular Effects of Incretin-Based Therapies: Friend or Foe?

  2017cites this paper
• Role of Proteases in Diabetes Mellitus

  2017cites this paper
• Potential involvement of JNK1 repression in the hepatic effect of sitagliptin and metformin in rats subjected to high fat diet and chronic mild distress.

  2017cites this paper
• Non-alcoholic fatty liver disease and diabetes.

  2017cites this paper
• Combination of Sitagliptin and Silymarin ameliorates liver fibrosis induced by carbon tetrachloride in rats.

  2017cites this paper
• Traitement de la stéatose et de la stéatohépatite non alcoolique par les traitements antidiabétiques

  2017cites this paper
• Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes.

  2016cites this paper
• Influence of the rs738409 polymorphism in patatin‐like phospholipase 3 on the treatment efficacy of non‐alcoholic fatty liver disease with type 2 diabetes mellitus

  2016cites this paper
• Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions

  2016cites this paper
• Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus.

  2016cites this paper
• Non-alcoholic fatty liver disease and diabetes

  2016influential citation
• Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models

  2016cites this paper
• Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus

  2016cites this paper
• Pharmacological management of nonalcoholic fatty liver disease.

  2016cites this paper
• DPP-4 inhibitors in diabetic complications: role of DPP-4 beyond glucose control

  2016cites this paper
• Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inh

  2016cites this paper
• GLP-1 based therapies: clinical implications for gastroenterologists

  2016cites this paper
• Povezanost inkretinske terapije i nealkoholne steatoze jetre u bolesnika sa šećernom bolesti tipa 2

  2016cites this paper
• Combination of Vildagliptin and Pioglitazone in Experimental Type 2 Diabetes in Male Rats

  2016cites this paper
• Fatty liver disease : from pathogenesis to pharmacotherapy

  2016influential citation
• FACULDADE DE MEDICINA DA UNIVERSIDADE DE COIMBRA TRABALHO FINAL DO 6o ANO MÉDICO COM VISTA À ATRIBUIÇÃO DO GRAU DE MESTRE NO ÂMBITO DO CICLO DE ESTUDOS DE MESTRADO INTEGRADO EM MEDICINA

  2015cites this paper
• Non-alcoholic fatty liver disease in 2015.

  2015cites this paper
• Nealkoholna masna bolest jetre

  2015cites this paper
• Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins

  2015cites this paper
• Promoting a Healthy Lifestyle, Managing Hyperlipidemia, Diabetes Mellitus, Hypertension, and Immunizations in Patients with Cirrhosis

  2015cites this paper
• Perspectives for managing of nonalcoholic fatty liver disease

  2015cites this paper
• Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.

  2015cites this paper
• Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease

  2015cites this paper
• Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease

  2015cites this paper
• Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway

  2015cites this paper
• Circulating dipeptidyl peptidase‐4 activity correlates with measures of hepatocyte apoptosis and fibrosis in non‐alcoholic fatty liver disease in type 2 diabetes mellitus and obesity: A dual cohort cross‐sectional study

  2015cites this paper
• Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury

  2015cites this paper
• Fatty liver disease in diabetes mellitus.

  2015cites this paper
• DPP4 in Diabetes

  2015cites this paper
• Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease.

  2015cites this paper
• Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease

  2015cites this paper
• Incretin‐based therapies for the treatment of non‐alcoholic fatty liver disease: A systematic review and meta‐analysis

  2015cites this paper
• Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus.

  2014cites this paper
• Pharmacologic Management of Non-Alcoholic Fatty Liver Disease

  2014cites this paper
• Non-Invasive Assessment of Hepatic Steatosis in Patients with NAFLD Using Controlled Attenuation Parameter and 1H-MR Spectroscopy

  2014cites this paper
• Effects of sitagliptin on ectopic fat contents and glucose metabolism in type 2 diabetic patients with fatty liver: A pilot study

  2014cites this paper
• Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus

  2014influential citation